A5100439381- Glycosylation and Glycoproteins Research
- Toxin Mechanisms and Immunotoxins
- Galectins and Cancer Biology
- Medicinal Plant Pharmacodynamics Research
- Polysaccharides and Plant Cell Walls
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related molecular mechanisms research
- Advanced biosensing and bioanalysis techniques
- ATP Synthase and ATPases Research
- Cancer-related gene regulation
- Autophagy in Disease and Therapy
- Cancer, Hypoxia, and Metabolism
- Wnt/β-catenin signaling in development and cancer
- Cancer Research and Treatments
- Urinary and Genital Oncology Studies
- Epigenetics and DNA Methylation
- HER2/EGFR in Cancer Research
- Proteoglycans and glycosaminoglycans research
- Fractal and DNA sequence analysis
- Estrogen and related hormone effects
- Nanocluster Synthesis and Applications
- Curcumin's Biomedical Applications
- Ginseng Biological Effects and Applications
- Ferroptosis and cancer prognosis
- Breast Cancer Treatment Studies
Central Hospital of Zibo
2025
Shanghai Zhabei District Shibei Hospital
2025
Shandong University of Traditional Chinese Medicine
2024
Yixing Tumor Hospital
2024
Dalian University of Technology
2024
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
2024
Binzhou University
2024
Binzhou Medical University
2024
Anhui Medical University
2021-2023
Beijing Friendship Hospital
2021-2023
High mobility group box 1 (HMGB1) is a nuclear DNA-binding protein with dual role in cancer, acting as an oncogene and tumor suppressor. This regulates nucleosomal structure, DNA damage repair, genomic stability within the cell, while also playing immune cell functions. review comprehensively evaluates biological clinical significance of HMGB1 including its involvement death survival, potential therapeutic target cancer biomarker, prosurvival signal for remaining cells after exposure to...
An enzyme-free platform composed of Cu metallization on hybridization chain reaction engineered dsDNA was fabricated for the amplified detection cancer cells and microRNAs.
Acute myeloid leukemia (AML), as the most common malignancy of hematopoietic system, poses challenges in treatment efficacy, relapse, and drug resistance. In this study, we have utilized 151 RNA sequencing datasets, 194 DNA methylation 200 somatic mutation datasets from AML cohort TCGA database to develop a multi-omics stratification model. This model enables comparison prognosis, clinical features, gene mutations, immune microenvironment sensitivity across subgroups. External validation...
Objective Thrombotic events (TEs) are common and severe complications of newly diagnosed multiple myeloma (NDMM). However, the impact thrombosis on survival patients remains controversial. The aim our study was to identify independent high-risk factors for as well explore association between incidence TEs in with NDMM.
Abstract Overexpression of nectin cell adhesion protein 4 correlates with cancer progression and poor prognosis in many human malignancies. Enfortumab vedotin (EV) is the first nectin-4–targeting antibody–drug conjugate (ADC) approved by FDA for treatment urothelial cancer. However, inadequate efficacy has limited progress other solid tumors EV. Furthermore, ocular, pulmonary, hematologic toxic side effects are common nectin-4–targeted therapy, which frequently results dose reduction and/or...
We designed and developed a novel DNA topoisomerase I inhibitor MF-6, which was more potent cytotoxin inducer of immunogenic cell death compared with DXd. To utilize MF-6's ability to induce antitumor immunity, human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate (ADC) trastuzumab-L6 that included cleavable linker MF-6 developed. Different from traditional cytotoxic ADC, the activity assessed by inducing tumor death, activating dendritic cells CD8+ T acquire...
FAM83D has been demonstrated to contribute tumorigenesis. However, its immune effects in hepatocellular carcinoma (HCC) have not reported. This study aimed identify the role of HCC. was over-expressed HCC and contributed poor prognosis according results data analysis based on The Cancer Genome Atlas (TCGA). Afterward, levels cells infiltration were found be correlated with expression level Through TISIDB cBioPortal network tools, a total 82 FAM83D-associated genes screened out, including 12...
In this study, a tobramycin concentration-dependent whole-cell micro-biosensor (tob-HHAz) was constructed by fusing aptamer with hammerhead ribozyme (HHR) from Schistosoma mansoni. The biosensor obtained integrating all the modules into one complete RNA sequence, which easily introduced E. coli without suffering harsh external environments. Three independent tobramycin-sensitive structures were identified via high-throughput screening in vivo and further verified vitro to undergo desired...
Currently, a lot of theoretical and technical issues still need to be addressed regarding applications DNA computing in the field cryptography.The current common cryptography algorithms are basically based on traditional cryptography, integrate dintoexisting technology, which feasibility has not yet been fully demonstrated.Through research analysis, we select biological puzzle that "DNA sequencing is difficult under conditions knowing correct primers probes".On basis chip technologies,...
<p>Comparison of the structure 9MW2821 and enfortumab vedotin.</p>
<p>Binding specificity based on enzyme-linked immunosorbent assay.</p>
<p>Binding affinity measured by Biolayer interferometry.</p>
<div>Abstract<p>Overexpression of nectin cell adhesion protein 4 correlates with cancer progression and poor prognosis in many human malignancies. Enfortumab vedotin (EV) is the first nectin-4-targeting antibody drug conjugate approved by US Food Drug Administration for treatment urothelial cancer. However, inadequate efficacy has limited progress other solid tumors EV. Furthermore, ocular, pulmonary, hematological toxic side effects are common nectin-4-targeted therapy, which...